Floatz logo

mk-2206

Stage IIIC Colon Cancer

National Cancer Institute (NCI)Small moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

47 Active assets in the Stage IIIC Colon Cancer cohort.

Asset / SponsorPhaseRating
Eloxatin
Sun Yat-sen University
Phase 3BBB
FLUOROURACILUM
Merck Sharp & Dohme LLC
Phase 3BBB
Irinotecan
Sun Yat-sen University
Phase 3BBB
Eloxatin
Merck Sharp & Dohme LLC
Phase 3BBB
Irinotecan
SWOG Cancer Research Network
Phase 3BBB

View all 50 →

Same molecule, other indications

mk-2206 is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
diffuse large B-cell lymphomaDormant
B
Indicative ·
60 / 100
View asset →
prostate cancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →